1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DDCAE871B314FF7300258ABE003AB28E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-oncology-field-medical-excellence-latam-mena-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2044.210.149.205
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Benchmarking Oncology Field Medical Excellence in LATAM and MENA: Establishing Standards for High Performance & Impact

ID: 5794


Features:

9 Info Graphics

23 Data Graphics

190+ Metrics

7 Narratives


Pages/Slides: 38


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Benchmarking Oncology Field Medical Excellence in LATAM and MENA: Establishing Standards for High Performance & Impact”

STUDY OVERVIEW

The Latin America (LATAM) and Middle East/North Africa (MENA) regions present a distinctive tapestry of challenges and opportunities within the oncology market, shaped by diverse healthcare systems, economic landscapes, cultural intricacies, and regulatory frameworks. In navigating this multifaceted terrain, optimizing the efficiency of field medical teams emerges as a critical imperative for oncology manufacturers seeking to flourish in these dynamic markets.

Best Practices, LLC undertook this benchmarking research to provide a comprehensive analysis of Oncology Field Medical Excellence in LATAM and MENA, empowering field medical leaders with actionable insights to drive impactful strategies. By identifying impactful performance metrics, devising optimal resourcing strategies, establishing frameworks for excellence, and analyzing engagement levels with KOLs, our study offers a roadmap for maximizing field medical impact in the LATAM and MENA regions.

KEY TOPICS

  • Effective Oncology Field Performance Metrics in the LATAM and MENA Regions
  • Building an Oncology Field Medical Excellence Framework
  • Target and Engagement Levels of Oncology KOLs in the LATAM and MENA Regions
  • Average Time Oncology MSLs Spend on KOL Interactions and Internal Activities in the LATAM and MENA Regions
  • Oncology Field Medical Staffing Footprint in the LATAM and MENA Regions
  • Key Insights and Lessons Learned for Measuring the Impact of Oncology MSLs in the LATAM and MENA Regions

KEY METRICS

  • LATAM and MENA field scorecard: Benchmarking oncology engagements
  • Average number of tiered vs. non-tiered KOLs per Oncology MSL in the LATAM and MENA regions
  • Monthly KOL and F2F interactions in the LATAM and MENA regions – Oncology segment
  • Weighting criteria for various interaction types on the Oncology MSL scorecard (LATAM and MENA regions)
  • Metrics for engaging non-tiered KOLs in the LATAM and MENA regions
  • Average Oncology MSL time in the field (days per year) in the LATAM and MENA regions
  • Percentage of Oncology MSL time spent on external, internal, and logistics activities (LATAM and MENA regions)
  • Weekly Oncology MSL time allocation for each activity stream in the LATAM and MENA regions
  • Percentage of overall oncology targets classified as KOLs, HCPs, payers, or other external stakeholders (LATAM and MENA regions)
  • Oncology field medical staffing footprint in the LATAM and MENA regions

SAMPLE KEY FINDINGS

  • Time Spent on External Engagement: Oncology Medical Science Liaisons (MSLs) in LATAM dedicate slightly over half of their time (52%) to direct external engagement. In MENA, Oncology MSLs allocate the highest portion of their time (63%) to direct external engagement.

METHODOLOGY

Best Practices, LLC collated performance data and insights from field medical executives from oncology companies around the world through a custom benchmark survey. Focused on oncology field medical operations, the research drew insights from a diverse range of respondents and was meticulously segmented at regional levels.


Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.